Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Healthcare Professionals Advised to Monitor Body Weight and Blood Sugar Levels in Patients Taking Seroquel
AstraZeneca Ltd has written to healthcare professionals to advise them that the safety information for Seroquel (quetiapine) has been updated to reflect the most up to date information on weight gain and raised blood sugar and cholesterol levels associated with this medicine. Healthcare professionals are advised to monitor body weight, blood sugar and cholesterol levels in patients taking Seroquel, and to manage the associated risks appropriately. Seroquel contains the medication quetiapine and is used in the treatment of schizophrenia, mania and depression. For more information please visit: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con140610.pdf
Learn More

Health Professionals Advised to Take Additional Caution When Using Strattera in Patients with High Blood Pressure and Circulatory Disease
Eli Lilly and Company Ltd has written to healthcare professionals to advise them of strengthened warnings and monitoring recommendations for the use of Strattera (atomoxetine). It was previously known that Strattera could cause a modest increase in blood pressure or heart rate, but recent studies have shown that these increases could cause adverse effects in certain patients. Healthcare professionals are therefore advised that Strattera should not be used in patients with severe heart or circulatory conditions, and that it should be used with caution in patients whose underlying medical condition (such as high blood pressure, fast heart beat, heart disease or previous stroke) could be made worse by an increase in blood pressure or heart rate. Blood pressure and heart rate should be monitored during treatment with Strattera. Strattera contains the medication atomoxetine and is used to treat attention deficit hyperactivity disorder (ADHD). For more information please visit: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con140593.pdf http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON140666
Learn More

Date Published Title Medicine Source
2012-01-12 Healthcare Professionals Advised to Monitor Body Weight and Blood Sugar Levels in Patients Taking Seroquel Quetiapine Manufacturer
2012-01-12 Health Professionals Advised to Take Additional Caution When Using Strattera in Patients with High Blood Pressure and Circulatory Disease Atomoxetine Manufacturer
2011-12-28 New Safety Information Leads To Recommendation of Treatment Review For All Patients Taking Rasilez Aliskiren MHRA
2011-12-22 Domperidone Linked to Abnormal Heart Rhythm and Sudden Cardiac Death Domperidone MHRA
2011-12-20 Teva Recalls Blister Packed Prednisolone 5mg and EC 2.5mg Tablets Over Stability Concern Prednisolone MHRA
2011-12-16 Evidence Does Not Suggest Angiotensin-II Receptor Antagonists Cause Increase in Cancer Risk Telmisartan MHRA
2011-12-16 Maximum Dose of Escitalopram Reduced After High Doses Linked to Abnormal Heart Rhythm Escitalopram MHRA
2011-12-16 Maximum Dose of Citalopram Reduced After High Doses Linked to Abnormal Heart Rhythm Citalopram MHRA
2011-12-13 FSC Black Cohosh Product Withdrawn From The U.K. Market Black Cohosh MHRA
2011-12-06 Healthcare Professionals Advised of the Limitations in The Use of Vectibix Panitumumab MHRA
2011-11-29 Busilvex and Velcade Recalled Following Contamination Concerns Doxorubicin MHRA
2011-11-15 MHRA Publishes UK Dosing Instructions For Children’s Liquid Paracetamol Paracetamol MHRA
2011-11-15 Neue Informationen zum Risiko von Blutgerinnseln bei Antibabypillen mit dem Wirkstoff Drospirenon Drospirenone with Ethinyl Estradiol AkdÄ
2011-11-14 Single Adrenaline Injection Pack Found to Contain Atropine Injection Primatene MHRA
2011-11-08 Healthcare Professionals Advised To Reduce Maximum Dose of Citalopram Citalopram Manufacturer
2011-11-08 Healthcare Professionals Advised Not to Use Pradaxa in Patients With Impaired Kidney Function Dabigatran Manufacturer
2011-11-08 Health professionals Advised of Increased Risk of Secondary Cancerous Tumours With Revlimid Lenalidomide Manufacturer
2011-11-07 Prescribers Advised to Stick to Recommended Doses of Revatio in Children After High Doses Linked to Fatality Sildenafil Manufacturer
2011-11-07 MHRA Advises Against Using Aqueous Calamine Cream Before X-rays Calamine MHRA
2011-11-07 No Change in Prescribing Practice for Calcium and Vitamin D Needed Calcium Citrate MHRA